Robert W. Duggan

Insider Reports History

Location
Clearwater, FL
Signature
/s/ Kenneth B. Stratton, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Robert W. Duggan:

Form 4 holding Co-Chief Executive Officer, Director, 10%+ Owner

Summit Therapeutics Inc.

Security class
Common Stock
Shares / value
25,724,474
Estimated value
$482,076,642
Report date
21 Oct 2025
Price
$18.74
Ownership
By the Mahkam Zanganeh Revocable Trust, with the Spouse of Reporting Person as Trustee
Form 4 holding Co-Chief Executive Officer, Director, 10%+ Owner

Summit Therapeutics Inc.

Security class
Common Stock
Shares / value
10,199,776
Estimated value
$210,727,372
Report date
21 Oct 2025
Price
$20.66
Ownership
By the Shaun Zanganeh Irrevocable Trust, with the Spouse of Reporting Person as Trustee
Form 4 holding Co-Chief Executive Officer, Director, 10%+ Owner

Summit Therapeutics Inc.

Security class
Stock Option (right to buy)
Shares / value
9,590,558
Estimated value
$110,051,658
Report date
29 Apr 2025
Price
$9.18
Ownership
By Spouse
Underlying class
Common Stock
Underlying amount
11,988,198
Form 4 holding Co-Chief Executive Officer, Director, 10%+ Owner

Summit Therapeutics Inc.

Security class
Common Stock
Shares / value
76,680
Estimated value
$1,436,983
Report date
21 Oct 2025
Price
$18.74
Ownership
Immediate family member of Spouse
Form 4 holding Co-Chief Executive Officer, Director, 10%+ Owner

Summit Therapeutics Inc.

Security class
Stock Option (right to buy)
Shares / value
11,232
Estimated value
$98,392
Report date
02 Jan 2026
Price
$8.76
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Co-Chief Executive Officer, Director, 10%+ Owner

Summit Therapeutics Inc.

Security class
Performance Stock Option (right to buy)
Shares / value
2,397,640
Estimated value
Report date
02 Jan 2025
Price
Ownership
By Spouse
Underlying class
Common Stock
Underlying amount
2,397,640
Form 4 holding Director, 10%+ Owner

PULSE BIOSCIENCES, INC.

Security class
Stock Option (right to buy)
Shares / value
20,792
Estimated value
Report date
15 Aug 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

PULSE BIOSCIENCES, INC.

Security class
Warrants (right to buy)
Shares / value
0
Estimated value
Report date
18 Dec 2024
Price
Ownership
Affiliated Company 1
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

PULSE BIOSCIENCES, INC.

Security class
Warrants (right to buy)
Shares / value
0
Estimated value
Report date
18 Dec 2024
Price
Ownership
Affiliated Company 2
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

PULSE BIOSCIENCES, INC.

Security class
Warrants (right to buy)
Shares / value
0
Estimated value
Report date
18 Dec 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Co-Chief Executive Officer, Director, 10%+ Owner

Summit Therapeutics Inc.

Security class
Warrant (right to buy)
Shares / value
0
Estimated value
Report date
08 Apr 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Robert W. Duggan

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .